ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Rare melanoma type highly responsive to immunotherapy europeanpharmaceuticalreview
April 30, 2019Moffitt Cancer Center researchers have discovered that patients with desmoplastic melanoma are more responsive to immune-activating anti-PD-1/PD-L1 therapies than previously assumed.
Pharma Sources Insight July 2025
